Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 2/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 5/20 | 0.36 |
| ▸ | NPC1 | O15118 | 4/20 | 0.36 |
| ▸ | RAB9A | P51151 | 4/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ALPL | P05186 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 5/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17895635 | 0.91 | MAPT (0.39) | MAPTNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL17895567 | 0.89 | CSNK1D (0.37) | NPC1RAB9ATP53CSNK1DKDM4E | |
| SCHEMBL17895609 | 0.88 | SLC6A2 (0.39) | PTPN1MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17895561 | 0.88 | RAB9A (0.36) | MAPTNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL17895667 | 0.87 | RAB9A (0.41) | MAPTNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL17895698 | 0.87 | NPC1 (0.41) | MAPTNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL17895616 | 0.86 | DYRK1A (0.36) | MAPTNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL17895663 | 0.85 | SLC6A2 (0.34) | MAPTNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL17895736 | 0.85 | DYRK1A (0.39) | MAPTNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL17895602 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11434234-B2 | Methods and agents for treating disease | ANGION BIOMEDICA CORP. (US) | 2022-09-06 | — | — | US | claimed |
| US-20210323955-A1 | METHODS AND AGENTS FOR TREATING DISEASE | ANGION BIOMEDICA CORP. | 2021-10-21 | — | — | US | claimed |
| CN-107531631-B | Methods and agents for treating diseases | 安吉昂生物医药公司 | 2021-09-03 | — | — | CN | claimed |
| US-10851095-B2 | Methods and agents for treating disease | ANGION BIOMEDICA CORP. (US) | 2020-12-01 | — | — | US | claimed |
| US-20190256507-A1 | METHODS AND AGENTS FOR TREATING DISEASE | ANGION BIOMEDICA CORP. (US) | 2019-08-22 | — | — | US | claimed |
| US-10287282-B2 | Methods and agents for treating disease | ANGION BIOMEDICA CORP. (US) | 2019-05-14 | — | — | US | claimed |
| US-20180002324-A1 | METHODS AND AGENTS FOR TREATING DISEASE | ANGION BIOMEDICA CORP. (US) | 2018-01-04 | — | — | US | claimed |
| US-11434234-B2 | Methods and agents for treating disease | ANGION BIOMEDICA CORP. (US) | 2022-09-06 | — | — | US | disclosed |
| US-20210323955-A1 | METHODS AND AGENTS FOR TREATING DISEASE | ANGION BIOMEDICA CORP. | 2021-10-21 | — | — | US | disclosed |
| CN-107531631-B | Methods and agents for treating diseases | 安吉昂生物医药公司 | 2021-09-03 | — | — | CN | disclosed |
| US-10851095-B2 | Methods and agents for treating disease | ANGION BIOMEDICA CORP. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20190256507-A1 | METHODS AND AGENTS FOR TREATING DISEASE | ANGION BIOMEDICA CORP. (US) | 2019-08-22 | — | — | US | disclosed |
| US-10287282-B2 | Methods and agents for treating disease | ANGION BIOMEDICA CORP. (US) | 2019-05-14 | — | — | US | disclosed |
| US-20180002324-A1 | METHODS AND AGENTS FOR TREATING DISEASE | ANGION BIOMEDICA CORP. (US) | 2018-01-04 | — | — | US | disclosed |
| EP-3240778-A1 | METHODS AND AGENTS FOR TREATING DISEASE | Angion Biomedica Corp. (US) | 2017-11-08 | — | — | EP | disclosed |
| WO-2016109492-A1 | METHODS AND AGENTS FOR TREATING DISEASE | ANGION BIOMEDICA CORP (US) | 2016-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180002324-A1 | METHODS AND AGENTS FOR TREATING DISEASE | REN, NR3C2, CYP11B2 | HCRTR1 2003/4885HCRTR2 1845/4885PTPN1 2604/4885 |
| US-11434234-B2 | Methods and agents for treating disease | REN, NR3C2, CYP11B2 | HCRTR1 1483/4885HCRTR2 1441/4885PTPN1 2381/4885 |
| US-10851095-B2 | Methods and agents for treating disease | REN, NR3C2, CYP11B2 | HCRTR1 1483/4885HCRTR2 1441/4885PTPN1 2381/4885 |
| US-10287282-B2 | Methods and agents for treating disease | REN, NR3C2, CYP11B2 | HCRTR1 2003/4885HCRTR2 1845/4885PTPN1 2604/4885 |
| US-20190256507-A1 | METHODS AND AGENTS FOR TREATING DISEASE | REN, NR3C2, CYP11B2 | HCRTR1 1483/4885HCRTR2 1441/4885PTPN1 2381/4885 |
| US-20210323955-A1 | METHODS AND AGENTS FOR TREATING DISEASE | REN, NR3C2, CYP11B2 | HCRTR1 1483/4885HCRTR2 1441/4885PTPN1 2381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.